THUMPD2

THUMPD2 is an RNA methyltransferase that installs the N2-methylguanosine (m2G) modification on U6 small nuclear RNA, thereby promoting spliceosome function and accurate pre-mRNA splicing (PMID:37283053, PMID:38165050). It directly associates with U6 snRNA and catalyzes m2G specifically at position G72, recognizing U6-specific sequence and structural elements, and its activity and metabolic stability depend on the co-factor TRMT112 (PMID:37283053, PMID:38165050). Loss of THUMPD2 eliminates U6 m2G72, alters thousands of alternative splicing events, and activates the nonsense-mediated mRNA decay pathway, establishing this single modification as functionally important for splicing fidelity (PMID:38165050). The protein contains three conserved methyltransferase motifs shared across prokaryotes and eukaryotes (PMID:12063391). Reported roles in chemoresistance and tumor cell behavior have not been connected to the U6 methyltransferase activity in the available corpus (PMID:31656051, PMID:39071668).

1. 2001 Medium

   Before any functional assignment, the gene now known as THUMPD2 (C2orf8) needed basic molecular definition, which established it as a candidate methyltransferase.

   Evidence RACE, RT-PCR, Northern blot, FISH and computational domain analysis of the C2orf8 locus

   PMID:12063391

   Open questions at the time

   • No enzymatic activity demonstrated
   • No substrate identified
   • No structural model of the catalytic motifs
2. 2021 Medium

   Whether THUMPD2 acts within a defined enzymatic module was unknown; it was placed in the TRMT112 methyltransferase interaction network, predicting a TRMT112-dependent activity.

   Evidence SILAC affinity pulldown and co-expression stability assays in cells

   PMID:34948388

   Open questions at the time

   • Substrate RNA/protein not identified in this study
   • Catalytic activity not directly demonstrated
   • Single lab
3. 2023 High

   The substrate and catalytic identity were open; THUMPD2 was shown to be an active m2G methyltransferase that associates with U6 snRNA and depends on TRMT112 for stability and activity.

   Evidence Interaction network mapping, in vitro methyltransferase assays, and demonstrated direct U6 snRNA association in intact cells

   PMID:37283053

   Open questions at the time

   • Exact modified position not pinpointed in this study
   • Structural basis of U6 recognition not resolved
4. 2024 High

   The precise modification site and physiological consequence were unresolved; THUMPD2 was shown to methylate G72 of U6 via specific recognition elements, with knockout disrupting splicing genome-wide and triggering NMD.

   Evidence THUMPD2 knockout in human cells, in vitro assays with U6 recognition-element mutagenesis, transcriptome-wide splicing analysis, and NMD activation readout

   PMID:38165050

   Open questions at the time

   • Structure of the THUMPD2–TRMT112–U6 complex not determined
   • Whether specific mis-spliced transcripts drive phenotypes is unclear
5. 2024 Low

   Beyond splicing, phenotypic roles were explored; THUMPD2 manipulation altered proliferation, metastasis, and chemoresistance in cancer cells, but without a molecular link to its U6 methyltransferase activity.

   Evidence siRNA/shRNA knockdown, overexpression, in vivo tumor growth assays, drug-resistance IC50 comparisons, and GO/KEGG pathway analysis across esophageal and ovarian cancer models

   PMID:31656051 PMID:39071668

   Open questions at the time

   • Single-knockdown approaches with limited mechanistic follow-up
   • No mechanistic connection between m2G/U6 splicing activity and the cancer phenotypes
   • Phenotypic readouts only

• It remains unknown how the THUMPD2-dependent U6 m2G72 modification mechanistically links to its reported roles in tumor proliferation, metastasis, and drug resistance.
• No structural model of the THUMPD2–TRMT112–U6 complex
• Cancer phenotypes not tied to splicing function
• Disease/Mendelian relevance uncharacterized